FDAnews
www.fdanews.com/articles/96312-medivation-announces-treatment-of-first-patient-in-phase-i-ii-of-mdv3100

Medivation Announces Treatment of First Patient in Phase I/II of MDV3100

July 25, 2007

Medivation announced treatment of the first patient in a Phase I/II clinical trial evaluating MDV3100, the company’s lead development candidate for hormone-refractory prostate cancer.

The U.S.-based, open-label, dose-escalation Phase I/II trial, which will enroll up to 62 patients, will evaluate the safety and tolerability of oral, once-daily MDV3100, Medivation said.

Endpoints include pharmacokinetics, the effect of MDV3100 on serum prostate-specific antigen (PSA) levels (a frequently-used surrogate marker of prostate cancer progression) and disease progression following treatment with MDV3100, the company added.
 
David Hung, president and CEO of Medivation, said the company expects PSA data from the first subset of patients by the end of the year.